Lixisenatide is a GLP-1 receptor agonist used for the management of type 2 diabetes mellitus. It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU.
- Mechanism
- Curator reviewed · 1 reference
The activation of the GLP-1 receptor by lixisenatide results in the activation of adenylyl cyclase. This increases the concentration of cyclic adenosine monophosphate in the cell leading to the activation of protein kinase A (PKA) as well as Epac1 and Epac2. PKA, Epac1, and Epac2 are involved the in release of Ca2+ from the endoplasmic reticulum which is known as the "amplification" pathway which increases insulin release when the triggering pathway is activated. By activating this amplification pathway lixisenatide increases glucose stimulated insulin secretion.
- Primary indication
- Lixisenatide is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type II diabetes mellitus.Curator reviewed · 2 structured indications
- Formula / weight
- 4858.0 Da
- First approval
- Canada, 2017 · United States, 2016 · European Union, 2020
- Code names
- AQVE-10010 · AVE 0010 · ZP 10 · ZP10A peptide
- Brand names
Resolves to
What you can answer from here — as of March 06, 2025
Which drugs share a target with Lixisenatide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account